Revenue ($USD) : $1,168,660,000
R&D spend : $50,131,000.00
Employees : 3,034
Fiscal year end : 04/01/23
CEO : Christopher Simon

Haemonetics technologies serve medical markets including blood and plasma component collection, the surgical suite and hospital transfusion.

News this year included FDA clearance of advancements to its NexSys PCS plasma collection system.

Haemonetics also invested €30 million in Galway, Ireland-based Vivasure and its portfolio of fully absorbable, patch-based, large-bore percutaneous vessel closure devices. The agreement includes an option for Haemonetics to acquire Vivasure. –CN and SW